BetterLife Pharma (BETRF)
(Delayed Data from OTC)
$0.07 USD
+0.01 (7.94%)
Updated Aug 8, 2025 11:43 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BETRF 0.07 +0.01(7.94%)
Will BETRF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BETRF based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BETRF
BetterLife Pharma Secures Patent for BETR-001, Strengthening Biotech Position
BetterLife Pharma Advances BETR-001 for Neuro-Psychiatric Disorders
BetterLife (BETRF) Showcases Promising Data for BETR-001 at Scientific Conference | BETRF Stock News
BetterLife provides update on neuroplastogenic activity of BETR-001
BetterLife provides update on neuroplastogenic activity of BETR-001